

## Form 604 – Notice of change of interests of substantial holder

---

**28 February 2025**

Pursuant to Section 671B of the *Corporations Act 2001* (Cth), Velocimetry Consulting Pty Ltd, Andreas Fouras and Helen Fouras provide the attached Form 604s. The forms disclose a decrease of their relevant interests in 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) due to the dilution of their interests arising from the issue of shares under the Company’s recent placement and other issues of shares since 4 March 2024.

For clarity, no shares held by Velocimetry Consulting Pty Ltd, Andreas Fouras or Helen Fouras in 4DMedical have been sold.

**-ENDS-**

Authorised by the 4DMedical Board of Directors.

### Contacts

#### Corporate

Chief Financial Officer  
Simon Glover  
[sglover@4dmedical.com](mailto:sglover@4dmedical.com)

#### Administration

Company Secretary  
Naomi Lawrie  
[companysecretary@4dmedical.com](mailto:companysecretary@4dmedical.com)

#### Media Enquiries

[4Dmedia@4dmedical.com](mailto:4Dmedia@4dmedical.com)

### About 4DMedical

4DMedical Limited (ASX:4DX) is a cutting-edge global medical technology company revolutionizing respiratory care. By harnessing advanced imaging and AI-powered solutions, 4DMedical delivers unprecedented insights into lung function, enabling earlier and more precise diagnoses of respiratory diseases.

At the heart of 4DMedical’s innovation is its patented XV Technology®, a groundbreaking platform that dynamically quantifies ventilation throughout the lungs as patients breathe. This technology underpins the company’s FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®) and its CT LVAS™, empowering physicians to detect and monitor regional airflow abnormalities with unparalleled sensitivity.

4DMedical’s solutions integrate seamlessly into existing hospital infrastructure via its Software as a Service (SaaS) model, transforming routine imaging into powerful diagnostic tools.

In December 2023, 4DMedical expanded its leadership in medical imaging with the acquisition of Imbio, a pioneer in artificial intelligence solutions for chronic lung and cardiothoracic diseases. Imbio’s AI-driven platforms enhance physician productivity, improve diagnostic precision, and support personalized care, aligning seamlessly with 4DMedical’s mission to redefine respiratory healthcare.

To learn more, please visit [www.4dmedical.com](http://www.4dmedical.com)

#### Melbourne

Level 7 Melbourne Connect  
700 Swanston Street  
Carlton VIC 3053  
Tel: +61 (3) 9545 5940

#### Los Angeles

21255 Burbank Boulevard  
Suite 120  
Woodland Hills CA 91367  
Tel: +1 (818) 403-8490

4DMedical Limited  
ABN: 31 161 684 831  
Email: [info@4DMedical.com](mailto:info@4DMedical.com)  
[www.4DMedical.com](http://www.4DMedical.com)

**Form 604**  
Corporations Act 2001  
Section 671B

**Notice of change of interests of substantial holder**

To: Company Name/Scheme 4DMedical Limited (4DX)  
ACN/ARSN ACN 161 684 831

**1. Details of substantial holder (1)**

Name Velocimetry Consulting Pty Ltd  
ACN/ARSN (if applicable) ACN 160 747 286

There was a change in the interests of the substantial holder on

28 / 02 / 25

The previous notice was given to the company on

19 / 12 / 23

The previous notice was dated

19 / 12 / 23

**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company of scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Fully Paid Ordinary Shares	65,701,465	16.81%	65,703,483	15.38%

**3. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
4 March 2024 – 20 June 2024	Velocimetry Consulting Pty Ltd	Dilution due to issuance of 510,865 ordinary shares.	N/A	65,701,465 ORD	65,701,465
28 June 2024	Velocimetry Consulting Pty Ltd	Dilution due to issuance of 19,000,000 ordinary shares.	N/A	65,701,465 ORD	65,701,465
4 July 2024 – 16 December 2024	Velocimetry Consulting Pty Ltd	Dilution due to issuance of 923,790 ordinary shares .	N/A	65,701,465 ORD	65,701,465
19 December 2024	Velocimetry Consulting Pty Ltd	Acquisition of shares by associate as part of 2025 Tax Exempt Share Plan.	N/A	2,018 ORD	2,018
19 December 2024	Velocimetry Consulting Pty Ltd	Dilution due to issuance of 280,502 ordinary shares.	N/A	65,703,483 ORD	65,703,483
31 December 2024 – 22 January 2025	Velocimetry Consulting Pty Ltd	Dilution due to issuance of 2,533,965 ordinary shares.	N/A	65,703,483 ORD	65,703,483
28 February 2025	Velocimetry Consulting Pty Ltd	Dilution in relevant interest due to issuance of 12,941,176 ordinary shares.	N/A	65,703,483 ORD	65,703,483

**4. Present relevant interest**

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
Velocimetry Consulting Pty Ltd ACN 160 747 286	Velocimetry Consulting Pty Ltd	Velocimetry Consulting Pty Ltd ACN 160 747 286	Relevant interest under section 608(1)(a) of the Corporations Act	64,838,000 ORD	65,703,483
	Helen Fouras	Helen Fouras (for more information see the ASIC Form 604 lodged by Helen Fouras on or around the same date as this ASIC Form 604).	Relevant interest of associate under section 11(a) of the Corporations Act	854,206 ORD	
	Andreas Fouras	Andreas Fouras (for more information see the ASIC Form 604 lodged by Andreas Fouras on or around the same date as this ASIC Form 604).	Relevant interest of associate under section 11(a) of the Corporations Act	11,277 ORD	

**5. Changes in association**

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Helen Fouras	Director of substantial holder
Andreas Fouras	Director of substantial holder

**6. Addresses**

The addresses of persons named in this form are as follows:

Name	Address
Velocimetry Consulting Pty Ltd ACN 160 747 286	C/- Agostinelli Perlen Pty Ltd of Level 1, 200 Lygon Street, Carlton VIC 3053
Helen Fouras	Suite 120, 21255 Burbank Boulevard, Woodland Hills, United States
Andreas Fouras	Suite 120, 21255 Burbank Boulevard, Woodland Hills, United States

**Signature**

print name Andreas Fouras Capacity Director of Velocimetry Consulting Pty Ltd

sign here 

date 28 / 02 / 25

**DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant issues (eg. A corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in Section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

- (6) Include details of:
- (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).
- See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg. If the relevant interest arises because of an option) write "unknown".
- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.